Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/37228
Title: | DCEP as a bridge to ongoing therapies for advanced relapsed and/or refractory multiple myeloma. | Authors: | Low M.S.Y.;Kalff A.;Bergin K.;Coutsouvelis J.;Spencer A.;Yuen H.L.A. ;Fedele P. ;Walker P.;Grigoriadis G. | Institution: | (Yuen, Kalff, Walker, Bergin, Grigoriadis, Spencer) Department of Clinical Haematology, Alfred Health, Melbourne, Australia (Yuen, Low, Fedele, Grigoriadis) Monash Haematology, Monash Health, Melbourne, Australia (Low, Grigoriadis) Hudson Institute of Medical Research and Southern Clinical School, Monash University, Clayton, Australia (Fedele) Walter and Eliza Hall Institute of Medical Research, University of Melbourne, Melbourne, Australia (Coutsouvelis) Centre for Medicine Use and Safety, Monash University, Clayton, Australia (Coutsouvelis) Pharmacy Department, Alfred Health, Melbourne, Australia (Spencer) Australian Centre for Blood Diseases, Monash University, Melbourne, Australia | Issue Date: | 3-Jan-2019 | Copyright year: | 2018 | Publisher: | Taylor and Francis Ltd | Place of publication: | United Kingdom | Publication information: | Leukemia and Lymphoma. 59 (12) (pp 2842-2846), 2018. Date of Publication: 02 Dec 2018. | Journal: | Leukemia and Lymphoma | Abstract: | There is limited data describing dexamethasone, cyclophosphamide, etoposide, and cisplatin (DCEP) in relapsed refractory multiple myeloma (RRMM). We reviewed 65 patients with RRMM receiving DCEP between 2005 and 2017 in two Melbourne Hospitals. Patients had received a mean of three prior treatment lines (range, 1-11). The mean number of cycles of DCEP was two (range, 1-4). Overall response rate (ORR) was 55% whilst 19% achieved MR and SD. Median overall survival (OS) was 9.6 months. Those bridged to autologous stem cell transplant (ASCT) had significantly improved OS compared to those who were not (median 32.8 vs. 10.7 months, p=.0004). Significant treatment-related mortality (TRM) was observed (9.7%), mostly attributable to grade 3-4 neutropenia and febrile neutropenia. Mandatory use of G-CSF is, therefore, warranted to prevent septic complications. In heavily pretreated RRMM, DCEP is an effective bridge to definitive therapy but in the absence of the latter, its value is questionable.Copyright © 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group. | DOI: | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1080/10428194.2018.1454595 | PubMed URL: | 29616871 [http://www.ncbi.nlm.nih.gov/pubmed/?term=29616871] | ISSN: | 1042-8194 | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/37228 | Type: | Article |
Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.